Literature DB >> 21256943

Deposition of aerosols delivered by nasal route with jet and mesh nebulizers.

Laurent Vecellio1, Ruth De Gersem, Sandrine Le Guellec, Gregory Reychler, Laurent Pitance, Deborah Le Pennec, Patrice Diot, Gilles Chantrel, Pierre Bonfils, François Jamar.   

Abstract

PURPOSE: To quantify the amount of aerosol deposited in different parts of the airways with a commercially available nasal sonic jet nebulizer (NJN) using a sound effect, and to compare its performance with a new nasal mesh nebulizer (NMN).
METHODS: Seven healthy non-smoking male volunteers aged 21-36 years with a mean weight of 77±10 kg were included in this single-center study. Both nebulizer systems were loaded with (99m)Tc-DTPA and scintigraphies were performed with a gamma camera. Particle size distribution of the aerosols produced by the two nebulizer systems was measured.
RESULTS: There was no statistical difference between the two nebulizers in terms of fraction of particles smaller than 5 μm (44±4% vs 45±2%) (p>0.9). Aerosol deposition in the nasal region was 73±10% (% of aerosol deposited in airways) with the NJN, and 99±3% with the NMN (p=0.01). Total nasal deposition was 9.6±1.9% of the nebulizer charge with the NJN and 28.4±8.9% with the NMN (p=0.01). 0.5±0.3% of the nebulizer charge was deposited in the maxillary sinuses with the NJN, compared to 2.2±1.6% with the NMN (p=0.01).
CONCLUSION: Although the two nebulizers had the same particle size, NMN significantly improved aerosol deposition in nasal cavity and prevents deposition into the lungs.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21256943     DOI: 10.1016/j.ijpharm.2011.01.024

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  7 in total

Review 1.  Antivirals and the Potential Benefits of Orally Inhaled Drug Administration in COVID-19 Treatment.

Authors:  Gokben Sahin; Ozlem Akbal-Dagistan; Meltem Culha; Aybige Erturk; Nur Sena Basarir; Serap Sancar; Ayca Yildiz-Pekoz
Journal:  J Pharm Sci       Date:  2022-06-09       Impact factor: 3.784

2.  Impact of airborne particle size, acoustic airflow and breathing pattern on delivery of nebulized antibiotic into the maxillary sinuses using a realistic human nasal replica.

Authors:  Lara Leclerc; Jérémie Pourchez; Gérald Aubert; Sandrine Leguellec; Laurent Vecellio; Michèle Cottier; Marc Durand
Journal:  Pharm Res       Date:  2014-03-04       Impact factor: 4.200

3.  Particle deposition in a child respiratory tract model: in vivo regional deposition of fine and ultrafine aerosols in baboons.

Authors:  Iolanda Albuquerque-Silva; Laurent Vecellio; Marc Durand; John Avet; Déborah Le Pennec; Michèle de Monte; Jérôme Montharu; Patrice Diot; Michèle Cottier; Francis Dubois; Jérémie Pourchez
Journal:  PLoS One       Date:  2014-04-30       Impact factor: 3.240

Review 4.  Inhalable Antimicrobials for Treatment of Bacterial Biofilm-Associated Sinusitis in Cystic Fibrosis Patients: Challenges and Drug Delivery Approaches.

Authors:  Sylvia Natalie Kłodzińska; Petra Alexandra Priemel; Thomas Rades; Hanne Mørck Nielsen
Journal:  Int J Mol Sci       Date:  2016-10-09       Impact factor: 5.923

5.  Numerical Analysis of Nasal Flow Characteristics with Microparticles.

Authors:  Yi Liu; Wan Lin Sun
Journal:  J Healthc Eng       Date:  2022-08-22       Impact factor: 3.822

6.  Nasal drug delivery devices: characteristics and performance in a clinical perspective-a review.

Authors:  Per Gisle Djupesland
Journal:  Drug Deliv Transl Res       Date:  2012-10-18       Impact factor: 4.617

7.  Validation of anatomical models to study aerosol deposition in human nasal cavities.

Authors:  Sandrine Le Guellec; Deborah Le Pennec; Stephane Gatier; Lara Leclerc; Maria Cabrera; Jeremie Pourchez; Patrice Diot; Gregory Reychler; Laurent Pitance; Marc Durand; François Jamar; Laurent Vecellio
Journal:  Pharm Res       Date:  2013-09-25       Impact factor: 4.200

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.